Memory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
|
|
- Christine Martin
- 5 years ago
- Views:
Transcription
1 Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair, Clinical and Translational Research Department of Neurological Sciences University of Nebraska Medical Center DISCLOSURE DECLARATION Dr. Murman has the following financial relationships: Grants/Research Support in the area of Alzheimer s disease clinical trial research: Eli Lilly & Co, Novartis, Roche, Genetech, and National Institutes of Health Learning Objectives: Understand the effects of aging on cognition and factors that can slow or accelerate decline Describe mild cognitive impairment and the most common causes of dementia List tools that can be used in evaluating cognitive decline in older adults Discuss the pathophysiology of Alzheimer s disease and experimental treatment approaches Know the important role of primary care providers in managing symptoms of dementia Cognition and Normal Aging Crystallized Abilities (Vocabulary) Fluid Abilities (Processing Speed) Age (years) Murman, Semin Hear 2015; 36: Neuronal Synapses Synapses, Age, and Health Healthy Aging Disease 1
2 Synaptic Density (% of maximal) Synaptic and Cognitive Reserve Synapses are created and strengthen with learning and mentally stimulating activities Having more synapses builds redundancy in neuronal connections and systems and creates cognitive reserve Synapses are gradually lost with normal aging and much more rapidly with disease Greater cognitive reserve delays symptoms onset in the face of neurodegenerative diseases such as Alzheimer s disease Cognitive Decline with Age and Disease Age (years) Normal Reserve/Normal Aging Normal Reserve/Normal Aging + AD Normal Reserve/Slower Aging Decreased Reserve/Normal Aging Dementia Threshold Murman, Semin Hear 2015; 36: Factors that Increase or Decrease Risk of Cognitive Decline Factors that Increase or Decrease Risk of Dementia Baumgart et al Alzheimer s & Dementia Baumgart et al Alzheimer s & Dementia Lifestyle for Brain Health Aging, MCI, and Dementia oexercise Regularly omentally Engaged ohealthy Diet osocially Connected ocontrol HTN, Lipids, DM ogood Sleep oavoid Toxins/Head Trauma Alzheimer s Association 2
3 Types of Dementia Dementia is the loss of memory due to changes in the brain Alzheimer s is the most common form Many mixed cases Many memory disorders are reversible and not truly dementia 3 Alzheimer s Disease Most common cause of dementia Gradual onset, gradual progression Memory loss first and most prominent symptom No focal findings or gait disorder early Genetic causes and genetic risk factors Becomes exponentially more common with age 3-5% of population at age % of population at age 85 AD Diagnostic Red Flags Abrupt onset, stroke symptoms Rapid progression Early gait changes, tremor, parkinsonism Early visual hallucinations, disinhibition, Early loss of expressive language Early myoclonus, seizures Clinical Features of AD vs VaD Feature Alzheimer s Disease Vascular Dementia Onset Gradual, insidious Sudden or gradual Progression Constant Slow, stepwise Focal Signs Usually absent Present Memory Deficits Early and severe Milder, Subcortical Executive Dysfunction Late Early and severe Neuroimaging Normal, atrophy Vascular abnormalities Lewy Body Dementia Importance of Non-AD Dementias Cerebrovascular disease is preventable Dementia with Lewy Body (DLB) patients are at increased risk of adverse medication reactions, delirium, falls, and institutionalization. DLB patients do respond to cholinesterase inhibitors Normal Pressure Hydrocephalus is treatable Rapidly progressive dementia may represent a treatable autoimmune condition or prion disease 3
4 Evaluation of Memory Loss History Time course, change in function, medications, depression, alcohol, sleep Physical Exam Test cognition, signs of stroke, stroke risk, parkinsonism, gait abnormalities Basic Labs CMP, TSH, vitamin B12 (B1, B6) Brain Imaging Head CT or Brain MRI Assessment Tools: Cognition Ascertain Dementia 8 (AD8) Questionnaire Mini-Cog Mini-Mental State Examination (MMSE) Montreal Cognitive Assessment (MoCA) Formal Neuropsychological Evaluation Assessment Tools: Function Functional Activities Questionnaire (FAQ) Functional Assessment Staging Tool (FAST) Assessment Tools: Psychiatric Neuropsychiatric Inventory Questionnaire (NPI-Q) * Structural Imaging Small Vessel, Vascular Dementia Mild Moderate Severe *Contains Copies of a Variety of Assessment Tools White Matter Lesions Large Vessel Infart CSF Biomarkers in AD Micro- Hemorrhage Small Vessel Infarct Lancet 2015; 386:
5 Functional Imaging FDG-PET Alzheimer s Disease Amyloid Plaques Auguste D. Alois Alzheimer Neurofibrillary Tangles What Alois Alzheimer s saw and described in 1906 Completely Independent Reminders Assistance with IADLs Supervision Assistance With Basic ADLs Completely Dependent AD: Facts and Figures In 2014, there are an estimated 5.2 million people living with AD in the US 5 million >65 years old; 200,000 < 65 years AD is very common in Midwest 33,000 cases in NE; 62,000 cases in IA In 2014, the direct cost of dementia of care in the US was estimated at $214 billion annually AD is the 6 th leading cause of death in US, and one third of elderly adults die with dementia From 2014 AD Facts and Figures, Alzheimer s Association ( Costs of Dementia Care Projected Increase in AD $214 Billion Per Year in US in $36 $37 $28 $113 Medicare Medicaid Out of Pocket Other From 2014 AD Facts and Figures, Alzheimer s Association ( 10 Millions Year Evans DA, et al. Milbank Q 1990; 68:
6 Amyloid Tau Genes and Amyloid b Amyloid Cascade Hypothesis APP Soluble p3 APP, PS1, PS2 mutations Ab 1-42 apoe e4 Plaque formation Neurofibrillary tangles Loss of synapses Inflammatory response Oxidative injury Neuronal death Toxic Effects of Amyloid b 1-42 PET Biomarkers in AD Biomarkers and Stages of AD Evolution of Amyloid and Tau Accumulation in AD Model of Disease Progression Healthy Control Asymptomatic Preclinical AD Asymptomatic Prodromal AD MCI Alzheimer s Disease Dementia Tau negative Focal tau Tau spreading Extensive tau Amyloid negative Amyloid positive Amyloid positive Amyloid positive 36 6
7 When Does AD Start? PET imaging studies in genetic forms of AD demonstrate accumulation of Ab years before expected age of symptom onset. Bateman RJ et al. NEJM 2012;367: Modeling of one large cohort study suggests that Ab deposition is detected 17 years before dementia diagnosis, hippocampal atrophy 4.2 years before, and memory impairment 3.3 years before (CDR 1). Villemagne VL et al. Lancet Neurol 2013;12: Right Target at Right Time Sperling RA, Jack CR, Aisen P Sci Transl Med 2011 AD Prevention Trials Focused on Amyloid b 1. Autosomal Dominant AD Treatment Trials PSEN1 E280A Kindred crenezumab sq Dominantly Inherited Alzheimer s Network (DIAN) solaneumab IV or gantenerumab sq 2. ApoE e4 Treatment Trial (e4/e4 carriers) Active immunization BACE (beta-secretase 1) inhibitor 3. Anti-Amyloid Treatment in Asymptomatic Alzheimer s disease Positive amyloid PET - solanezumab IV AD Clinical Trial Resources Prevention Trials for Alzheimer s disease (AD) Alzheimer s Prevention Registry GeneMatch Generation Study Trials for Patient s with an AD diagnosis Alzheimer s Association TrialMatch Primary Care Management of Patients with Cognitive Impairment is Vital! Location of first contact with the healthcare system for most patients with dementia symptoms Can identify and treat conditions worsening dementia symptoms Medications are available to help many symptoms of dementia including impairments of cognition, behavior and functional abilities Can provide education, support, community resource referrals and help keep patient in home environment longer Quality Indicators in AD Care Time Line Study Time Line Dementia Dx (ICD-9 code) and continually enrolled 2 yrs Grant begins Survey Y1 Y2 Y3 Quality of Life Grant ends Data Analysis, Presentation Chart Abstraction Process of Care Receipt of Quality Indicators Outcomes Caregiver Satisfaction Costs of Care 7
8 1. Evaluating Dementia Symptoms Dementia Assessments % Receiving Specific Diagnosis Made 89 Lab Test (B12, TSH) 78 Brain Imaging (CT or MRI) 74 Annual assessment of cognition* 40 Annual assessment of behavior* 39 Annual assessment of function* 46 *New Consensus Quality Measure 2. Supporting Patients and Families Psychosocial Interventions % Receiving Education Provided 80 Referral to Community Resources 62 Driving Safety Addressed* 74 Alternative Decision Maker Discussed* 67 Advanced Directives Discussed* 53 *New Consensus Quality Measure 3. Medication Use in Dementia Care Pharmacologic Treatment % Receiving Cholinesterase Inhibitor Prescribed 91 Persistent Use of Cholinesterase Inhibitor 35 Memantine for Mod. to Severe AD 52 Medication Used for Severe Psychiatric Symptoms* 57 Anti-Cholinergic Medications Avoided 89 FDA-approved Medications for AD Cognex (tacrine) * Aricept (donepezil) * Exelon (rivastigmine) * Razadyne (galantamine) * Namenda (memantine) 2003* *FDA approval date *New Consensus Quality Measure Management of: Neuropsychiatric Symptoms in AD Try to understand triggers for negative behaviors Environmental changes and engaging activities are usually more effective than medications Rule out medical condition, pain, other discomfort There are no FDA-approved medications for the treatment of neuropsychiatric symptoms in AD Treatment of: Neuropsychiatric Symptoms in AD Effective antidepressant medications are available for depression, anxiety, and agitation, with low risk of side effects Severe agitation or aggressive behavior can be controlled with atypical antipsychotic medications, but with moderate risk of side effects Antipsychotic medications may decrease hallucinations, delusions, and paranoia, but with moderate risk of side effects 8
9 4. Managing Co-Morbid Conditions Co-Morbid Disease Mgmt. % Receiving Antiplatelet Rx (DM, CHD, CVD) 81 If Diabetes, then yearly HgA1c 87 If Diabetes, then BS control (A1c<9%) 72 If Hypertension, then BP control <140/90 63 If DM, CHD, CVD, then lipid testing 89 Lipid control (LDL<130), if high risk grp 51 Hospital Stays, Dementia & Delirium All cause admissions rates are higher for older adults with dementia than those without (OR 1.41) Patients with dementia that are hospitalized and develop delirium have poorer outcomes: longer lengths of stay, faster cognitive and functional decline, institutionalization and death. Admission rates for ambulatory care sensitive conditions are higher for patients with dementia (OR 1.78) Fink DM, J Hosp Med 2013;8: Phelan EA, JAMA 2012;307: Fong TG, Ann Intern Med 2012; 156: Patient Outcome Mean (Std. Dev.) Patient s Health Related Quality of Life Euroqol (EQ5D; 0-1 scale) 0.61 ± 0.22 Visual Analog Scale (0-100 scale) 52 ± 20.0 Satisfaction with Patient s Healthcare Satisfaction with Health Plan (0-10 scale) 8.14 ± 2.02 Satisfaction with Primary Provider (0-10) 8.10 ± 1.99 Patient s Costs of Care Two Year Total Costs (7/2003 6/2005): $21,479 ± $45,164 Annual Costs (7/2004 6/2005) Skilled Nursing Facility $296 ± $1,565 ER $614 ± $1,507 Outpatient Services $1,838 ± $1,781 Other $1,927 ± $22,212 Prescription Drug $2,182 ± $2,128 Hospitalizations $3,485 ± $8,950 Total Costs (7/2004 6/2005): $10,566 ± $24,778 Dementia Care Indexes and Outcomes Index Measure Mean +Std. Dev. Correlations with Outcomes Satisfaction (Health Plan) 2-Year Costs (Log) AD-Care IQ Index 69.5 ± (percent of 22) p<0.01 p=0.79 Dementia Core ± (0-12) p<0.01 p=0.39 Dementia Core ± (0-6) p<0.01 p=0.49 Opportunities to Improve Care Educate providers that dementia is a chronic condition that requires ongoing assessments and disease management, not diagnose and adios. Utilize brief, assessment tools for evaluating cognition, function and psychiatric symptoms. Reimburse healthcare providers for the extra time required for dementia care in ambulatory setting. Opportunities To Improve Care Facilitate the referral of patients with dementia to community resources. Partner with caregivers and monitor their health. Consider the use of effective medications for Alzheimer s disease and related dementias, especially in patients with moderate to severe symptoms. Effectively manage co-morbid medical conditions in patients with dementia to lower the risk of hospitalization and poor outcomes 9
10 Learning Objectives: Understand the effects of aging on cognition and factors that can slow or accelerate decline Describe mild cognitive impairment and the most common causes of dementia List tools that can be used in evaluating cognitive decline in older adults Discuss the pathophysiology of Alzheimer s disease and experimental treatment approaches Know the important role of primary care providers in managing symptoms of dementia Questions? For questions related to this presentation you can contact Dr. Daniel Murman at dlmurman@unmc.edu, (academic office), (clinic) Appendix: Resources AD8 Mini-Cog MMSE MoCA FAQ FAST NPI-Q AD8 Brief (8 questions), informant-based questionnaire about changes in behavior or functions that may represent dementia Reliable and valid for screening for dementia Can be administered to patient directly, also Score of 2 or higher suggests need for dementia evaluation Galvin et al. Neurology 2006; 67: Mini-Cog Brief Screening Tool (3 minutes or less) Includes two tasks: 1. Three word registration and delayed recall 2. Clock Drawing Test Scores range from 0 to 5. Scores less than 3 would indicate indicate probable dementia and the need for further evaluation. A cut point of less than 4 can be used to improve the sensitivity of this screening test. 10
11 Mini Mental Status Examination Evaluates orientation, memory, attention, language, visual-spatial function Take 5 10 minutes to complete Higher scores are better, 30/30 is perfect score, 24/30 or less suggests dementia Widely used and understood Average change is 2.5 to 3 points per year in patients with Alzheimer s disease Montreal Cognitive Assessment More challenging then MMSE and has more items to assess executive cognitive function, attention and visual spatial function Available online in multiple languages Takes about 10 minutes to complete Thirty points possible, higher scores better, scores less than 26 suggest at least mild cognitive impairment Short MoCA Functional Activities Questionaire Caregiver completed scale of functional abilities (instrumental ADLs) Rating designate whether patient is completely independent, needs some help, or is unable to complete task. Scores higher than 9 suggest significant functional impairment. Pfeffer R, et al. J Gerontol 1982;37: Functional Assessment Staging (FAST) Seven functional levels but level 6 has five items and level 7 has six items (i.e. 16 total items) Psychometric properties of scale poorly understood Levels can be divided into stages of dementia: 3,4 = Mild Dementia 5,6 = Moderate Dementia 7 = Severe Dementia Reisberg, B. Functional assessment staging (FAST). Psychopharmacology Bulletin. 1988; 24: Neuropsychiatric Inventory - Questionnaire (NPI-Q) Caregiver completed questionnaire Asks about presence and severity of neuropsychiatric symptoms in 12 domains Also measures caregiver distress related to these symptoms Can be used to identify and monitor neuropsychiatric symptoms Kaufer DI, et al. J Neuropsychiatry Clin Neursci 2000; 12:
WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More information3/6/2019 DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING FINANCIAL DISCLOSURES LEARNING OBJECTIVES
DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING MILTA LITTLE, DO, CMD DUKE UNIVERSITY SCHOOL OF MEDICINE FINANCIAL DISCLOSURES Dr. Little has no relevant financial disclosures to report Dr. Little will
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationDementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP
Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia
More informationCaring Sheet #11: Alzheimer s Disease:
CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses
More informationMemory Loss, Dementia and Alzheimer's Disease: The Basics
Memory Loss, Dementia and Alzheimer's Disease: The Basics What is memory loss? What is age-related memory loss? Typical changes Typical age-related changes involve: Making a bad decision once in a while
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationDementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
More informationUnderstanding Dementia
Understanding Dementia Dr. Dallas Seitz MD FRCPC Assistant Professor, Department of Psychiatry, Queen s University, Kingston, Ontario, Canada What s Next Information about Dementia, Elder Care and Supports
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationI have no relevant financial disclosures
1 ADVANCED INSIGHTS INTO THE PREVENTION, TREATMENT AND MANAGEMENT OF ALZHEIMER S DISEASE Naushira Pandya, MD, CMD, FACP Professor and Chair, Department of Geriatrics Director, Geriatrics Education Center
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationOLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.
Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple
More informationEvaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:
Alzheimer s Disease A Public Health Response July 19, 2007 1 2 Guest Speakers Thanks to our Sponsors: Earl A. Zimmerman, M.D. Bender Endowed Chair of Neurology and Director of the Alzheimer s Center at
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationMOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
More informationDementia: It s Not Always Alzheimer s
Dementia: It s Not Always Alzheimer s A Caregiver s Perspective Diane E. Vance, Ph.D. Mid-America Institute on Aging and Wellness 2017 My Background Caregiver for my husband who had Lewy Body Dementia
More informationPart 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University
Part 2: Early detection, assessment and treatment in relation to the new guidelines Christopher Patterson McMaster University C. Patterson MD, FRCPC Division of Geriatric Medicine, McMaster University
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationDementia and Delirium
Dementia and Delirium LPT Gondar Mental Health Group www.le.ac.uk Dementia and Delirium WTINP Chapter 4.6 Introduction - areas to be covered Delirium Definition and causes Clinical features Management
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationAlzheimer s Disease - Dementia
- Dementia Neurocognitive disorder with dysfunction or loss of " Memory " Orientation " Attention " Language " Judgment " Reasoning Other characteristics that can manifest " Personality changes " Behavioral
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationObjective 4/22/2019. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation.
Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory
More informationInteraction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation
Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory
More informationAlzheimer s disease is an
Alzheimer s Disease FACT SHEET Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationVascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center
Vascular Dementia Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center none Disclosures Objectives To review the definition of Vascular Cognitive Impairment (VCI);
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationDementia Past, Present and Future
Dementia Past, Present and Future Morris Freedman MD, FRCPC Division of Neurology Baycrest and University of Toronto Rotman Research Institute, Baycrest CNSF 2015 Objectives By the end of this presentation,
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationDementia Diagnosis Guidelines Primary Care
Dementia Diagnosis Guidelines Primary Care Dementia Diagnosis Primary Care Guidelines Introduction Dementia is a long term condition, which primarily affects people over the age of 65 (late on-set dementia)
More informationScreening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral
More informationThe Person: Dementia Basics
The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer
More informationDiagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology
Diagnosis and management of non-alzheimer dementias Melissa Yu, M.D. Department of Neurology AGENDA Introduction When to think of alternate diagnoses Other forms of dementia Other reasons for confusion
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationDementia: Diagnosis and Treatment
Dementia: Diagnosis and Treatment Outline 1. Risk factors and definition of dementia 2. Types of Dementias 3. MMSE and testing 4. Treatment options Cognitive decline with aging Mild changes in memory and
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More informationPersonal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders
Personal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders Dr. David B. Hogan Brenda Strafford Foundation Chair in Geriatric Medicine University of Calgary None to declare
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationDr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital. November /20/ Safety: Falls/Cooking/Unsafe Behaviour. 2.
How To Decide if an Elderly Person Can Stay at Home: The Interval of Need Concept Dr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital November 2013 3 Factors 1. Safety: Falls/Cooking/Unsafe Behaviour
More informationSignificance A Busy Clinician's Guide to Seniors with Memory Loss
Significance A Busy Clinician's Guide to Seniors with Memory Loss Victoria Braund MD FACP CMD Division of Geriatrics. NorthShore University HealthSystem Alzheimer's disease is the sixth leading cause of
More informationDrug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle
Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationA BRIEF LOOK AT DEMENTIA
Dementia A BRIEF LOOK AT DEMENTIA David Kaufman, MD Neurology Consultants of Bellin Health November 2, 2017 Defined as a progressive decline in cognitive function that impairs daily activities. Always
More informationDementia Chronic Brain Failure The forgotten cardiovascular disease Clare Hawley 2015
Dementia Chronic Brain Failure The forgotten cardiovascular disease Clare Hawley 2015 MB ChB, MRCGP, PG Dip Cardiol, PG Cert Med Ed Associate Specialist Cardiology Chesterfield Royal Hospital GPwSI Refractory
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationEARLY DEMENTIA. University of Hawaii Geriatric Medicine Department
EARLY DEMENTIA University of Hawaii Geriatric Medicine Department INTRODUCTION Dementia is very prevalent Screening and early diagnosis is important Evaluation Dementia Management DEMENTIA IS VERY PREVALENT
More informationWhat is Neuropsychology?
Alzheimer s Disease Neurological Bases and Informed Behavioral Interventions Peter T. Keenan Clinical Neuropsychologist Marshfield Clinic Minocqua Center What is Neuropsychology? Science of the relationship
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More informationCognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
More informationWHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationSubject Index A abuse 18, 38 active ageing 16, 17, 19, 44 activity of daily living 17 ADI (Alzheimer s Disease International) 45 advance care-planning
Subject Index A abuse 18, 38 active ageing 16, 17, 19, 44 activity of daily living 17 ADI (Alzheimer s Disease International) 45 advance care-planning 118, 120 African medicine 92 ageing active ageing
More informationDelirium, Depression and Dementia
Delirium, Depression and Dementia Martha Watson, MS, APRN, GCNS Some material included in this presentation is adapted from: NICHE (2009). Geriatric Resource Nurse Core Curriculum [Power Point presentation].
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationUnderstanding Alzheimer s Disease
Understanding Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disorder that slowly impacts memory, thinking, skills and, eventually, the ability to carry out the simplest
More informationLatest Methods to Early Detection for Alzheimer's: Cognitive Assessments and Diagnostic Tools in Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/alzheimers-disease-towards-earlier-detection/latest-methods-earlydetection-alzheimers-cognitive-assessments-and-diagnostic-tools-practice/8321/
More information11/12/2018. Acknowledgements. Risk factors for Alzheimer s disease
Is it Possible to Reduce My Risk for Alzheimer's Disease? An Overview of Current Risk Reduction Strategies Dorothy Farrar Edwards PhD, Professor of Medicine and Kinesiology Core Leader: Outreach, Recruitment
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationApproach to Cognitive Disorders in Primary Care
Approach to Cognitive Disorders in Primary Care What can reasonably be done in an office visit? What about screening for cognitive disorders? USPSTF (2014) doesn t recommend screening: magnitude of clinically
More informationWelcome to the Your Health Lecture Series!
Welcome to the Your Health Lecture Series! Tonight s Lecture: Alzheimer s Disease: A Look into the Future Moderator: Dr. Jean Nagelkerk Vice Provost for Health Grand Valley State University Event Begins
More information